Humacyte (HUMA)
NASDAQ:HUMA
Want to see HUMA full AI Analyst Report?
HUMA Stock Chart & Stats
$0.71
-$0.19(-4.01%)
At close: 4:00 PM EST
$0.71
-$0.19(-4.01%)
Day’s Range― - ―
52-Week Range$0.55 - $2.84
Previous CloseN/A
Volume1.64M
Average Volume (3M)8.03M
Market Cap
$234.23M
Enterprise Value$235.76M
Total Cash (Recent Filing)$48.54M
Total Debt (Recent Filing)$65.90M
Price to Earnings (P/E)―
Beta2.88
Next Earnings
Aug 17, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding222,019,100
10 Day Avg. Volume9,355,040
30 Day Avg. Volume8,028,307
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)48.86
Price to Sales (P/S)74.54
P/FCF Ratio-1.43
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue116.95
Enterprise Value/Gross Profit-15.62
Enterprise Value/Ebitda-2.96
Forecast
1Y Price Target
$2.67Price Target Upside275.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.36
Revenue Forecast (FY)$6.50M
Bulls Say, Bears Say
Bulls Say
Positive Phase 3 (V012) Interim ResultsEarly, positive V012 topline results that met the primary endpoint and prompted protocol-specified early stopping materially improve the likelihood of a supplemental BLA in H2 2026. Regulatory success in a large hemodialysis indication would create a durable commercial expansion path and stronger payer interest given lower infections and fewer catheter days.
Regained Global Rights To SymvessReclaiming global commercialization rights centralizes strategic control, enabling Humacyte to align pricing, licensing and partner strategies across markets. This reduces fragmentation risk, preserves upside from international launches, and allows targeted partnerships or direct market entry to capture long-term revenue from a differentiated off-the-shelf vascular graft.
Early Commercial Traction & Strategic EngagementsSequential unit and revenue growth across expanding sites, combined with government funding and a Saudi purchase commitment, strengthen go-to-market and credibility with hospitals and payers. Alongside senior commercial hires, these durable commercial and strategic engagements accelerate surgeon adoption, institutional evaluations, and international rollout potential.
Bears Say
High Leverage Relative To EquityDebt materially outweighs equity, constraining financial flexibility and elevating refinancing risk. With a small equity base, downside scenarios could force dilutive financings or restrict investment in manufacturing and commercialization, hindering strategic execution over the next several quarters.
Large, Persistent Cash BurnVery negative operating and free cash flow indicate ongoing reliance on external capital to fund operations. Even with recent financings, the current burn rate will likely require further funding, compressing runway and forcing management to prioritize near-term commercialization over longer-term R&D investments.
Minimal Revenue; Deep Losses And Negative Gross ProfitRevenue remains immaterial relative to costs and losses, and negative gross profit shows product costs and inventory write-downs exceed sales. Until scale reduces unit costs and margins improve, sustained profitability is unlikely and operating leverage will remain poor, pressuring long-term commercial viability.
Humacyte News
HUMA FAQ
What was Humacyte’s price range in the past 12 months?
Humacyte lowest stock price was $0.55 and its highest was $2.84 in the past 12 months.
What is Humacyte’s market cap?
Humacyte’s market cap is $234.23M.
When is Humacyte’s upcoming earnings report date?
Humacyte’s upcoming earnings report date is Aug 17, 2026 which is in 62 days.
How were Humacyte’s earnings last quarter?
Humacyte released its earnings results on May 13, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.116 by $0.026.
Is Humacyte overvalued?
According to Wall Street analysts Humacyte’s price is currently Undervalued.
Does Humacyte pay dividends?
Humacyte does not currently pay dividends.
What is Humacyte’s EPS estimate?
Humacyte’s EPS estimate is -0.09.
How many shares outstanding does Humacyte have?
Humacyte has 222,019,100 shares outstanding.
What happened to Humacyte’s price movement after its last earnings report?
Humacyte reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.116. Following the earnings report the stock price went up 24.176%.
Which hedge fund is a major shareholder of Humacyte?
Currently, no hedge funds are holding shares in HUMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Humacyte Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.67 (275.59% Upside)
$2.67 (275.59% Upside)
Blogger Sentiment
Bullish
HUMA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 5.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $59.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 6.3%
Last 30 Days ▲ 6.3%
News Sentiment
Very Bullish
Bullish news 88%
Bearish news 12%
Bearish news 12%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-56.22%
12-Months-Change
Fundamentals
Return on Equity
-2781.56%
Trailing 12-Months
Asset Growth
-31.99%
Trailing 12-Months
Company Description
Humacyte
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
HUMA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted tangible commercial momentum (Symvess unit and revenue growth), strengthened commercial leadership, international regulatory progress (Israel MAA accepted), strategic government interest (DoD funding), and important near-term clinical catalysts (V012 interim results due June 11 and CTEV Phase I/II planned H2 2026). These operational and pipeline advances were balanced against financial headwinds in the quarter: a swing to a $17.6M net loss driven largely by reduced noncash other income, a large inventory reserve that inflated COGS, increased R&D spend for CTEV manufacturing, and modest absolute product revenue despite high percentage growth. The company has taken actions (restructuring, senior hires, targeted commercialization) to address uptake and cost structure and reported a cash position of $48.9M. Overall, progress on product, pipeline, and commercialization initiatives combined with cost-saving actions and an upcoming trial readout lead to a cautiously optimistic view of the company’s near-term prospects, tempered by the recent negative impact on profitability and remaining timing uncertainties around regulatory and procurement milestones.View all HUMA earnings summariesHUMA Stock 12 Month Forecast
Average Price Target
$2.67
▲(275.59% Upside)
Technical Analysis
Cartesian Therapeutics
―
Allogene Therapeutics
―
―
Foghorn Therapeutics
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
9.88% Insiders
5.76% Mutual Funds
6.35% Other Institutional Investors
70.02% Public Companies and
Individual Investors